Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

What remains matters: Real-world impact of measurable residual disease testing in multiple myeloma

View Full Paper
Ask AI
Bookmark
Share

Authors

EVEvan VietoriszYKYulia Kuznetsova

Discussion

Loading...

Member takes

Overview

Observational analysis highlights extended time to next treatment in multiple myeloma with MRD testing, suggesting optimized treatment choices.

Key Points

  • MRD testing improves overall survival in patients with multiple myeloma, highlighting its relevance in clinical practice.
  • Among the 11,952 patients, 20% underwent MRD testing, revealing deep insights into treatment outcomes.
  • The observational study utilized patient-level data from the Flatiron Health Research Database, ensuring robust analysis.
  • MRD-guided strategies could bolster treatment personalization, warranting further exploration in future studies.

Cite This Study

Vietorisz et al. (2025) studied this question.

synapsesocial.com/papers/69362f574fa91c937236da68https://doi.org/10.1182/blood-2025-2789
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Measurable residual disease in newly diagnosed multiple myeloma: Experience from a large cohort from an academic medical center2025
  2. 2Patterns of minimal residual disease trajectories in 323 newly diagnosed patients with multiple myeloma and correlation with progression-free survival2025
  3. 3Minimal Residual Disease Negativity as the Primary Goal of Multiple Myeloma Therapy2025 · 6 citations
  4. 4MRD dynamics predicts progression and reveals a vulnerable state for immunotherapy interception in multiple myeloma2026
  5. 5Cytogenetics-based clinical trajectories of patients with MRD negativity post autologous stem cell transplant for multiple myeloma2025